Rituximab plus venetoclax for untreated marginal zone lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, rituximab and venetoclax, as a first treatment for marginal zone lymphoma that has not been treated before. The goal is to see if this drug pair is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with marginal zone lymphoma, a type of slow-growing non-Hodgkin lymphoma.
- You must have at least one enlarged lymph node that is 1.5 cm or larger, or an enlarged spleen (over 13 cm), so doctors can measure your disease.
- You must not have had any prior chemotherapy or immunotherapy (like rituximab) for your lymphoma. Some local radiation therapy may be okay if it was done at least a week before the study.
- You must be at least 18 years old, have a good performance status (ECOG 0 or 1), and have a life expectancy of more than 2 years.
- Your blood counts and organ function (kidney, liver, bone marrow) must be within certain limits, as checked by blood tests.
- You must be able to swallow pills and be willing to follow effective contraception rules if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medicines—pirtobrutinib (a targeted pill) and rituximab (an infusion)—for people with marginal zone lymphoma who have not had any prior systemic treatment. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for marginal zone lymphoma. The goal is to see how well this drug pair works for people who have not received any prior cancer therapy.
This trial tests a combination of two drugs—nemtabrutinib (a BTK inhibitor that targets cancer cells) and rituximab (an antibody drug)—to treat marginal zone lymphoma, a type of blood cancer. The study aims to see if this combination works better than standard treatments.
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.